ImmunoGen (IMGN) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1-year price objectives for ImmunoGen's shares. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's share price to reach $16.43 in the next year. This suggests that the stock has a possible downside of 4.3%.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $4.96 on January 1st, 2023. Since then, IMGN stock has increased by 246.0% and is now trading at $17.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Friday, April, 28th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. The biotechnology company had revenue of $49.90 million for the quarter, compared to analysts' expectations of $21.63 million. ImmunoGen had a negative net margin of 198.88% and a negative trailing twelve-month return on equity of 135.94%. The company's quarterly revenue was up 31.0% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS.

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

ImmunoGen issued an update on its FY 2023 earnings guidance on Friday, April, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $108.34 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.96%), State Street Corp (7.55%), Wellington Management Group LLP (4.36%), Maverick Capital Ltd. (3.48%), Geode Capital Management LLC (1.79%) and Artisan Partners Limited Partnership (1.41%).
View institutional ownership trends.

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $17.16.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.88 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

The company employs 106 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.